7 research outputs found
Involvement of LPA Receptor 3 in LPA-induced BGC- 803 Cell Migration
Lysophosphatidic acid
Ë„
LPA
Ë…
is a bioactive phospholipid mediator, which elicits a
variety of biological functions mainly through G-protein coupled receptors. Although
LPA is shown to stimulate proliferation and motility via LPA receptors, LPAR1 and
LPAR3 in several cancer cell lines, but the role of LPA receptors in gastric cancer
cells is still being unknown. However, several researches reported that LPAR2 play
an important role in the carcinogenesis of gastric cancer, but there is no report to
show the LPAR3 involvement in the carcinogenesis. For this reason, we examined
LPA receptors (LPAR1, LPAR2 and LPAR3) in BGC-803 cells along with real time
PCR method. Real-time PCR analyses were used to evaluate the expression of LPA
receptors in BGC-803 cells. Among these receptors, LPAR3 was shown to be highly
expressed in BGC-803 cells, a human gastric cancer cell line.
Transient transfection
with LPAR3 siRNA was observed to reduce LPAR3 mRNA in BGC-803 cells and
eliminate the LPA-induced cell migration. The results suggest that the LPAR3
regulates LPA-induced BGC-803 cell migration
Controllable Synthesis of a Smart Multifunctional Nanoscale Metal–Organic Framework for Magnetic Resonance/Optical Imaging and Targeted Drug Delivery
As a result of their extraordinarily
large surfaces and well-defined
pores, the design of a multifunctional metal–organic framework
(MOF) is crucial for drug delivery but has rarely been reported. In
this paper, a novel drug delivery system (DDS) based on nanoscale
MOF was developed for use in cancer diagnosis and therapy. This MOF-based
tumor targeting DDS was fabricated by a simple postsynthetic surface
modification process. First, magnetic mesoporous nanomaterial Fe-MIL-53-NH<sub>2</sub> was used for encapsulating the drug and served as a magnetic
resonance contrast agent. Moreover, the Fe-MIL-53-NH<sub>2</sub> nanomaterial
exhibited a high loading capacity for the model anticancer drug 5-fluorouracil
(5-FU). Subsequently, the fluorescence imaging agent 5-carboxyfluorescein
(5-FAM) and the targeting reagent folic acid (FA) were conjugated
to the 5-FU-loaded Fe-MIL-53-NH<sub>2</sub>, resulting in the advanced
DDS Fe-MIL-53-NH<sub>2</sub>-FA-5-FAM/5-FU. Owing to the multifunctional
surface modification, the obtained DDS Fe-MIL-53-NH<sub>2</sub>-FA-5-FAM/5-FU
shows good biocompatibility, tumor enhanced cellular uptake, strong
cancer cell growth inhibitory effect, excellent fluorescence imaging,
and outstanding magnetic resonance imaging capability. Taken together,
this study integrates diagnostic and treatment aspects into a single
platform by a simple and efficient strategy, aiming for facilitating
new possibilities for MOF use for multifunctional drug delivery